6-(butylamino)pyrazine-2-carboxamide | 1537902-03-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 6-(butylamino)pyrazine-2-carboxamide
• CAS: 1537902-03-6
• 化学式: C₉H₁₄N₄O
• 分子量: 194.236
• InChiKey: VUUFCHLZEDSNOP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  80.9
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  6-氯吡嗪-2-羧酸 在 ammonium hydroxide 、 氯化亚砜 、 三乙胺 、 N,N-二甲基甲酰胺 作用下， 以 乙醇 、 二氯甲烷 、 甲苯 为溶剂， 反应 9.0h， 生成 6-(butylamino)pyrazine-2-carboxamide
  参考文献：
  名称：

  Alkylamino derivatives of pyrazinamide: Synthesis and antimycobacterial evaluation

  摘要：

  A series of pyrazinamide derivatives with alkylamino substitution was designed, synthesized and tested for their ability to inhibit the growth of selected mycobacterial, bacterial and fungal strains. The target structures were prepared from the corresponding 5-chloro (1) or 6-chloropyrazine-2-carboxamide (2) by nucleophilic substitution of chlorine by various non-aromatic amines (alkylamines). To determine the influence of alkyl substitution, corresponding amino derivatives (1a, 2a) and compounds with phenylalkylamino substitution were prepared. Some of the compounds exerted antimycobacterial activity against Mycobacterium tuberculosis H37Rv significantly better than standard pyrazinamide and corresponding starting compounds (1 and 2). Basic structure-activity relationships are presented. Only weak antibacterial and no antifungal activity was detected. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.12.054

文献信息

• 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders
  申请人：Chen L. Yuhpyng

  公开号：US20050107381A1

  公开（公告）日：2005-05-19

  The present invention relates to compounds of the Formula wherein R 1 , R 1a , R 1b , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , X, Y, W, U, Z, m and n are as defined. Compounds of the Formula I have activity inhibiting production of Aβ-peptide. This invention also relates to pharmaceutical compositions and methods of treating diseases, for example, neurodegenerative diseases, e.g., Alzheimer's disease, in a mammal comprising compounds of the Formula I.

  本发明涉及公式I的化合物，其中R1，R1a，R1b，R2，R3，R4，R5，R6，R7，R8，R9，R10，R11，R12，X，Y，W，U，Z，m和n如所定义。公式I的化合物具有抑制Aβ肽生成活性。本发明还涉及含有公式I化合物的制药组合物和治疗疾病的方法，例如神经退行性疾病，例如阿尔茨海默病，在哺乳动物中治疗。
• Alkylamino derivatives of pyrazinamide: Synthesis and antimycobacterial evaluation
  作者：Barbora Servusová、Pavla Paterová、Jana Mandíková、Vladimír Kubíček、Radim Kučera、Jiří Kuneš、Martin Doležal、Jan Zitko

  DOI：10.1016/j.bmcl.2013.12.054

  日期：2014.1

  A series of pyrazinamide derivatives with alkylamino substitution was designed, synthesized and tested for their ability to inhibit the growth of selected mycobacterial, bacterial and fungal strains. The target structures were prepared from the corresponding 5-chloro (1) or 6-chloropyrazine-2-carboxamide (2) by nucleophilic substitution of chlorine by various non-aromatic amines (alkylamines). To determine the influence of alkyl substitution, corresponding amino derivatives (1a, 2a) and compounds with phenylalkylamino substitution were prepared. Some of the compounds exerted antimycobacterial activity against Mycobacterium tuberculosis H37Rv significantly better than standard pyrazinamide and corresponding starting compounds (1 and 2). Basic structure-activity relationships are presented. Only weak antibacterial and no antifungal activity was detected. (C) 2013 Elsevier Ltd. All rights reserved.